CN114555061A - 一种奥利司他胶囊及其制备方法 - Google Patents

一种奥利司他胶囊及其制备方法 Download PDF

Info

Publication number
CN114555061A
CN114555061A CN201980042418.XA CN201980042418A CN114555061A CN 114555061 A CN114555061 A CN 114555061A CN 201980042418 A CN201980042418 A CN 201980042418A CN 114555061 A CN114555061 A CN 114555061A
Authority
CN
China
Prior art keywords
orlistat
leucine
propylene carbonate
hydroxypropyl cellulose
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980042418.XA
Other languages
English (en)
Other versions
CN114555061B (zh
Inventor
张贵民
陈小伟
李泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong New Time Pharmaceutical Co Ltd
Original Assignee
Shandong New Time Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong New Time Pharmaceutical Co Ltd filed Critical Shandong New Time Pharmaceutical Co Ltd
Publication of CN114555061A publication Critical patent/CN114555061A/zh
Application granted granted Critical
Publication of CN114555061B publication Critical patent/CN114555061B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种药物制剂领域技术，公开了一种奥利司他的胶囊及其制备方法。通过奥利司他与羟丙基纤维素、白氨酸和碳酸丙烯酯形成复合物的方法减小原料粒径，提高药物的亲水性和流动性以及稳定剂，解决奥利司他制备、存储过程中的稳定性；制备工艺简单，制得的奥利司他胶囊溶出迅速、稳定性好。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201980042418.XA 2019-10-18 2019-10-18 一种奥利司他胶囊及其制备方法 Active CN114555061B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/112028 WO2021072773A1 (zh) 2019-10-18 2019-10-18 一种奥利司他胶囊及其制备方法

Publications (2)

Publication Number Publication Date
CN114555061A true CN114555061A (zh) 2022-05-27
CN114555061B CN114555061B (zh) 2023-08-15

Family

ID=75538191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980042418.XA Active CN114555061B (zh) 2019-10-18 2019-10-18 一种奥利司他胶囊及其制备方法

Country Status (2)

Country Link
CN (1) CN114555061B (zh)
WO (1) WO2021072773A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073937A2 (en) * 2005-12-27 2007-07-05 Krka Tovarna Zdravil Process for preparing crystalline forms of orlistat
WO2010084502A1 (en) * 2009-01-22 2010-07-29 Biocon Limited A crystalline form of orlistat and a process thereof
CN101791296A (zh) * 2010-01-17 2010-08-04 山东新时代药业有限公司 一种奥利司他片剂及其制备方法
CN102552168A (zh) * 2012-01-31 2012-07-11 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
CN106349192A (zh) * 2016-10-10 2017-01-25 中山万汉医药科技有限公司 奥利司他与氨基酸的共晶体及包含该共晶体的药物组合物
CN108785272A (zh) * 2018-09-04 2018-11-13 中山万汉制药有限公司 一种奥利司他软胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103222964B (zh) * 2013-01-29 2014-10-08 青岛大学 一种奥利司他口服制剂及其制备方法
CN108440456B (zh) * 2018-03-22 2020-01-03 中山万汉制药有限公司 奥利司他与有机酸钙的共晶体及包含该共晶体的药物组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073937A2 (en) * 2005-12-27 2007-07-05 Krka Tovarna Zdravil Process for preparing crystalline forms of orlistat
WO2010084502A1 (en) * 2009-01-22 2010-07-29 Biocon Limited A crystalline form of orlistat and a process thereof
CN101791296A (zh) * 2010-01-17 2010-08-04 山东新时代药业有限公司 一种奥利司他片剂及其制备方法
CN102552168A (zh) * 2012-01-31 2012-07-11 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
CN106349192A (zh) * 2016-10-10 2017-01-25 中山万汉医药科技有限公司 奥利司他与氨基酸的共晶体及包含该共晶体的药物组合物
CN108785272A (zh) * 2018-09-04 2018-11-13 中山万汉制药有限公司 一种奥利司他软胶囊及其制备方法

Also Published As

Publication number Publication date
WO2021072773A1 (zh) 2021-04-22
CN114555061B (zh) 2023-08-15

Similar Documents

Publication Publication Date Title
TWI388324B (zh) 含有泊沙康唑（ｐｏｓａｃｏｎａｚｏｌｅ）之高密度組合物及包含該組合物之調配物
JP2001511156A (ja) 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法
JPH0122245B2 (zh)
US8663698B2 (en) Solid dispersion preparation
US11883399B2 (en) Bromocriptine formulations
WO2014104671A1 (ko) 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
US20070248682A1 (en) Solid preparation comprising enteric solid dispersion
US20120294935A1 (en) Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
KR20220150388A (ko) 약학적 조성물, 제조 방법 및 이의 사용 방법
CN104888228A (zh) 一种甲苯磺酸索拉非尼固体分散体及其制备方法
WO2009084036A2 (en) Composition for treatment of viral infections
CN114555061B (zh) 一种奥利司他胶囊及其制备方法
WO2016029494A1 (zh) 微晶纤维素在制备美索舒利制剂中的用途及其制备方法
CN101653580A (zh) 一种治疗胃病的药物及其制备方法
CN116173018A (zh) 一种达罗他胺药物组合物及其制备方法和用途
CN112516148B (zh) 美洛昔康固体药物组合物及其制备方法
CN111150713B (zh) 一种吲达帕胺胶囊及其制备方法
CN104288141B (zh) 一种辛伐他汀固体药物组合物及其制备方法
CN112870167A (zh) 一种谷维素固体分散体及其制备方法与应用
WO2007049626A1 (ja) カベルゴリン含有経口固形製剤
CN113893222B (zh) 一种药物组合物及其制备方法和用途
US20230330029A1 (en) Resveratrol composition, preparation method and application thereof
CN116687961A (zh) 一种含有兰索拉唑及碳酸氢钠的干混悬剂及其制备方法
WO2022072099A9 (en) Immediate release dosage forms, methods of making and using
JP2022545822A (ja) チダミド医薬組成物、その調製方法及びその適用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant